New immune drug TNX-1500 tested for safety in first human study
NCT ID NCT07473752
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested the safety of a new drug called TNX-1500 in 26 healthy adults. Participants received either a single dose of the drug or a placebo. The goal was to see if the drug is safe and how the body processes it, not to treat any disease. This is a first step before testing it in people with illnesses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TNX-1500 (an anti-CD154 antibody)
- What this could lead to
- If successful, this could pave the way for testing TNX-1500 in conditions where immune system modulation is needed, such as autoimmune diseases or transplant rejection.
- What could go wrong
- This is a very early Phase 1 study in only 26 healthy people, focused on safety, not effectiveness. The drug may not work in patients or could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHASE 1 FIRST-IN-HUMAN STUDY INVOLVING HEALTHY SUBJECTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CTI Clinical Research Center
Cincinnati, Ohio, 45212, United States